HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+15.22%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$280M
AUM Growth
+$280M
(+1.8%)
Cap. Flow
-$16.9M
Cap. Flow
% of AUM
-6.04%
Top 10 Holdings %
Top 10 Hldgs %
28.7%
Holding
166
New
40
Increased
28
Reduced
35
Closed
35
Top Buys
| 1 |
Apogee Therapeutics
APGE
|
$7.93M |
| 2 |
ANSS
Ansys
ANSS
|
$4.44M |
| 3 |
JNPR
Juniper Networks
JNPR
|
$4.25M |
| 4 |
VanEck Gold Miners ETF
GDX
|
$2.78M |
| 5 |
Keros Therapeutics
KROS
|
$2.6M |
Top Sells
| 1 |
Spyre Therapeutics
SYRE
|
$16.1M |
| 2 |
Immunovant
IMVT
|
$5.11M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$4.29M |
| 4 |
SPLK
Splunk Inc
SPLK
|
$4.2M |
| 5 |
SOVO
Sovos Brands, Inc. Common Stock
SOVO
|
$4.07M |
Sector Composition
| 1 | Healthcare | 44.78% |
| 2 | Technology | 11.84% |
| 3 | Consumer Discretionary | 7.8% |
| 4 | Industrials | 6.17% |
| 5 | Financials | 4.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
101
Abivax
ABVX
$6.32B
| $826K | 0.29% |
+57,762
| New | +$826K |
|
102
Geron
GERN
$893M
| $793K | 0.28% |
240,234
| – | – |
|
103
Repare Therapeutics
RPTX
$73.9M
| $778K | 0.28% |
165,173
| – | – |
|
104
Crinetics Pharmaceuticals
CRNX
$3.26B
| $744K | 0.27% |
15,899
| – | – |
|
105
Immuneering
IMRX
$229M
| $736K | 0.26% |
254,513
| – | – |
|
106
Krystal Biotech
KRYS
$4.35B
| $698K | 0.25% |
+3,923
| New | +$698K |
|
107
Ascendis Pharma
ASND
$12.1B
| $684K | 0.24% |
4,527
+1,699
| +60% | +$257K |
|
108
Madrigal Pharmaceuticals
MDGL
$9.7B
| $677K | 0.24% |
2,534
+1,103
| +77% | +$295K |
|
109
Vaxcyte
PCVX
$4.17B
| $637K | 0.23% |
9,321
| – | – |
|
110
Rhythm Pharmaceuticals
RYTM
$6.75B
| $622K | 0.22% |
14,362
| – | – |
|
111
Protagonist Therapeutics
PTGX
$3.62B
| $614K | 0.22% |
21,229
-7,130
| -25% | -$206K |
|
112
KE Holdings
BEKE
$21.8B
| $588K | 0.21% |
42,807
-11,300
| -21% | -$155K |
|
113
Baidu
BIDU
$33.1B
| $578K | 0.21% |
5,486
-1,400
| -20% | -$147K |
|
114
Trip.com Group
TCOM
$46.6B
| $554K | 0.2% |
12,629
-11,500
| -48% | -$505K |
|
115
Mersana Therapeutics
MRSN
$34.8M
| $548K | 0.2% |
+4,893
| New | +$548K |
|
|
VRNA
116
Verona Pharma
VRNA
$9.18B
| $522K | 0.19% |
32,449
| – | – |
|
117
Syndax Pharmaceuticals
SNDX
$1.39B
| $512K | 0.18% |
+21,519
| New | +$512K |
|
118
Mirum Pharmaceuticals
MIRM
$3.75B
| $508K | 0.18% |
+20,208
| New | +$508K |
|
119
Pliant Therapeutics
PLRX
$105M
| $507K | 0.18% |
34,039
| – | – |
|
|
TSVT
120
DELISTED
2seventy bio
TSVT
| $500K | 0.18% |
+93,500
| New | +$500K |
|
121
4D Molecular Therapeutics
FDMT
$287M
| $495K | 0.18% |
15,532
-24,810
| -61% | -$790K |
|
122
Revolution Medicines
RVMD
$7.43B
| $462K | 0.16% |
14,325
-8,325
| -37% | -$268K |
|
123
Soleno Therapeutics
SLNO
$3.56B
| $446K | 0.16% |
+10,428
| New | +$446K |
|
124
Apellis Pharmaceuticals
APLS
$3.51B
| $427K | 0.15% |
+7,266
| New | +$427K |
|
125
New Oriental
EDU
$7.98B
| $408K | 0.15% |
4,700
-2,400
| -34% | -$208K |
|